The Inflation Reduction Act: The Emerging Implications for Biopharmaceutical Innovation

This panel will take a focused look at the potential implications of the Inflation Reduction Act (IRA) of 2022 on biopharmaceutical innovation. While the full impact of the IRA is not yet clear, drug developers, patient advocates and other stakeholders are watching for the potential impact on small molecule drug development, on overall development of cancer therapies, on patient care for major chronic diseases, among other concerns.

The Inflation Reduction Act: The Emerging Implications for Biopharmaceutical Innovation

Marina III/IV Ballroom